Pyrimidines as EGFR inhibitors and methods of treating disorders

A method of treating non-small cell lung cancer comprising administering to a subject in need thereof an effective amount of a compound of Formula I:

• or pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, or tautomers thereof, wherein:
• Z1 and Z2 are each independently N and Z3 is CR8;
• R8 is H, (C1-C4) alkyl, (C1-C4) haloalkyl, or halogen;
• R1 is H, (C1-C4) alkyl, (C1-C4) haloalkyl, NH2, NH(C1-C4) alkyl, N((C1-C4) alkyl)2, or halogen;
• R2 is H or (C1-C6) alkyl;
• R3 is (C1-C4) alkoxy, (C1-C4) alkyl, (C1-C4) haloalkyl, or halogen;
• R4 is NR9R10 or a 5- to 7-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S and optionally substituted with one or more R11;
• R9 is H or (C1-C4) alkyl;
• R10 is (C1-C4) alkyl, (C1-C4) alkyl-NH(C1-C4) alkyl, or (C1-C4) alkyl-N((C1-C4) alkyl)2;
• or R9 and R10 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocycle optionally comprising 1 or 2 additional heteroatoms selected from N, O, and S and optionally substituted with one or more R11;
• each R11 is independently (C1-C4) alkyl, (C1-C4) haloalkyl, (C1-C4) alkoxy, or halogen;
• R5 is NR12C(O)R13 or C(O)NR12R13;
• R12 is H or (C1-C6) alkyl;
• R13 is (C1-C5) alkyl or (C2-C6) alkenyl, wherein the alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN, and NH2;
• R6 and R7 together with the nitrogen atom to which they are attached form a substituent of the formula
• wherein
• X3 is N;
• X1, X2, X4, X5 and X6 are each independently CH;
• and
• each R15 is independently (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, OH, NH2, NH(C1l -C6) alkyl, N((C1-C6) alkyl)2, or halogen.